Dose Escalation of IPI-493 in Hematologic Malignancies

Stopped early · Phase 1

Conditions studied: Hematologic Malignancies

In brief

The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.

Key facts

Study ID

NCT01193491

Run by

Infinity Pharmaceuticals, Inc.

People needed

4

Starts

2010-06-01

Expected to finish

2011-07-01

Last updated by the study team

2015-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >/=18 years old
• ECOG 0-1
• confirmed hematological malignancy
• refractory to available therapy or for which no therapy is available
• adequate hepatic, renal function

You may not qualify if…

• active CNS malignancy
• prolonged QT interval
• significant GI/liver disease
• other serious concurrent illness or medical condition

Where it is running

• Johns Hopkins Sidney Kimmel Cancer Center — Baltimore, Maryland, United States
• Weill Cornell Cancer Center — New York, New York, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.